Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers

Treatment of acute lymphoblastic leukaemia with the second generation of CD19 CAR‐T containing either CD28 or 4‐1BB

“…In contrast to our previous CAR‐T study in solid tumours (Zhang et al , ), immunosuppressive markers were increased in most patients after cultivation and after infusion. Spearman correlation analysis revealed the relationship between CAR expression and immunosuppressive markers.…”

“…Details of lentivirus production and cell cultivation have been previously described (Zhang et al , ). For Patients 1–5, anti‐CD19 scFv originating from FMC63 antibody was inserted into the pCDH lentiviral vector with a G4 h (IgG4 hinge), 28TM (CD28 transmembrane domain), and CD28 and CD3 zeta intracellular signalling domains.…”

Donor-derived CAR-T Cells Serve as a Reduced-intensity Conditioning Regimen for Haploidentical Stem Cell Transplantation in Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: Case Report and Review of the Literature

“…The blood collection for the CAR-T cell preparation was performed before mobilization, and the production, detection, and quantification of the CD19-CAR-T cells were performed according to our previous report. 16 The mobilization and apheresis of the donor peripheral mononuclear cells and bone marrow were performed according to our previous report. 17 This study was approved by the Institutional Review Board of Xinqiao Hospital and was conducted in accordance with the Declaration of Helsinki.…”

Adoptive immunotherapy with CAR modified T cells in cancer current landscape and future perspectives

“…In sarcoma, anti-HER2 CAR T cells showed a reassuring safety profile (134) and led to CR in one case (135), while anti-GD2 constructs demonstrated significant clinical activity in 5 out of 11 patients with active neuroblastoma, including 3 CR (136). Signs of activity were also shown in recent studies involving epithelial tumors (137)(138)(139)(140). The concept of the central nervous system (CNS) as an immune privileged site has been overturned in recent years, since T cells can penetrate the blood-brain barrier and infiltrate the brain in a diffuse manner (141); as a matter of fact, one of the most promising field of CAR T cells development in solid malignancies are CNS tumors.…”